Agreements reached under this partnership
Capital and Business Alliance- 1
Research and development
- 2
Manufacturing support
- 3
Phased consideration and implementation in areas including the creation of new businesses
- 4
Securing recurring demand for culture media and related materials in the field of animal regenerative medicine
- 5
Generating stable revenue from raw materials and manufacturing support as Vetanic products progress toward practical application
- 6
Establishing a competitive advantage by expanding involvement in upstream processes, including quality assessment and standardization
- 7
Examining the potential application of technologies originating in the veterinary medicine field to human regenerative medicine
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
At present, the impact of this matter on the Company's financial results is limited. However, depending on progress in research and development and the status of commercialization, it may lead to expanded revenue opportunities over the medium to long term.
| Item | Details |
|---|---|
| Name of alliance partner | 株式会社 Vetanic, SYSMEX CORPORATION |
| Alliance partner's business activities | A business aiming to commercialize iPS cell-derived regenerative medicine products in veterinary medicine, based on proprietary technology for establishing animal iPS cells (Vetanic). A business centered on the clinical laboratory testing field, with analytical and quality assessment technologies (SYSMEX CORPORATION). |
| Alliance partner's location | Minato-ku, Tokyo (Vetanic); Kobe, Hyogo Prefecture (SYSMEX CORPORATION) |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | Research and development, Manufacturing support, Phased consideration and implementation in areas including the creation of new businesses, Securing recurring demand for culture media and related materials in the field of animal regenerative medicine, Generating stable revenue from raw materials and manufacturing support as Vetanic products progress toward practical application, Establishing a competitive advantage by expanding involvement in upstream processes, including quality assessment and standardization, Examining the potential application of technologies originating in the veterinary medicine field to human regenerative medicine |
| Acquisition price | Not disclosed at the request of the other party |
| Contract Date | 1 April 2026 |
| Impact on Business Performance | At present, the impact of this matter on the Company's financial results is limited. However, depending on progress in research and development and the status of commercialization, it may lead to expanded revenue opportunities over the medium to long term. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to develop the existing business alliance and strengthen the medium- to long-term cooperative relationship through an equity investment. The parties aim to deepen involvement in the commercialization and practical application phases of products in the regenerative medicine-related business, deepen the business portfolio and achieve sustainable growth.